That's kind of a stunner. They have been describing themselves as an oncology company off and on in their corporate PRs for a while now since Helen came on board, so there's that. OTOH where is the cash for acquisitions going to come from? One could guess that they are extremely confident in the outcome of the current phase III and that the money taps will be flowing freely after that. Beyond that, I'm pretty surprised to say the least. Anybody else have any thoughts?
News 
Market Data 
Discover 
AI
